Tuesday, November 2, 2021

FDA staffers sing Pfizer/BioNTech COVID shot’s praises ahead of key committee meeting

The FDA has released its internal review documents ahead of the closely watched COVID-19 vaccine advisory committee meeting scheduled for Thursday—and they bode well for Pfizer and partner BioNTech’s prospects for securing a quick emergency use authorization (EUA).

The FDA meeting briefing, published (PDF) on Tuesday, confirmed the efficacy and safety profile of Pfizer and BioNTech’s BNT162b2, reiterating that the shot was 95% effective at preventing COVID-19 after two doses with no serious safety concerns.

Sponsored by Clinical Ink

Deploy Configurable, Fit-for-Purpose ePRO Solutions, Fast.

Clinical Ink’s enhanced Lunexis™ ePRO+ module streamlines processes through a flexible, unified platform that allows patients and sites a high degree of optionality.

And reviewers were full of praise for the vaccine’s clinical program. BNT162b2’s development has “ensured the highest compliance and quality standards while progressing expeditiously” to address the pandemic, the agency wrote in its executive summary.

Statistical analysis suggests the vaccine’s true efficacy is at least 90.3% with a possibility of hitting as high as 97.5%. Notably, the efficacy was consistently high at 94.7% for participants at 65 years of age or older. And even in those with underlying conditions who are considered at risk of developing serious COVID cases, the vaccine’s efficacy stood strong at 95.3%.

Similar protection levels that mostly hovered above 93% were also observed across sex and racial/ethnic groups. In all, 1 case of severe COVID-19 occurred in the vaccine group, while the placebo group recorded 9 cases at the data cutoff.

FDA staffers described the data as suggesting “highly effective protection against COVID-19 in a broad population of individuals across demographic characteristics.”

RELATED: Pfizer, BioNTech nab COVID-19 vaccine authorization from U.K. for first-ever marketed mRNA shot

The FDA reviewers also noticed an early onset of protection that’s “readily apparent” after the first dose of vaccination. COVID cases for the BNT162b2 and placebo groups were tracking together until about 14 days after the first dose. After that, cases in the Pfizer/BioNTech shot’s study arm reached a plateau, whereas the numbers in the placebo arm continued upward.  

Aside from efficacy, safety is a key focus of the public’s attention on COVID-19 vaccines, especially for the brand-new mRNA technology on which BNT162b2 is based. And the need for robust safety data, as required by the FDA, has previously also been highlighted by Pfizer CEO Albert Bourla.

Immediate manifestation of an inflammatory response to vaccination was mostly mild to moderate and short-lived for BNT162b2 in its pivotal trial. Serious side effects were infrequent, and their incidence was comparable between the BNT162b2 and placebo groups, though the incidence of any side effect was higher for the vaccine group.

As part of its EUA application, Pfizer and BioNTech included a plan for safety surveillance that will monitor reports of serious side effects.

Overall, the data “support a positive assessment of risk and benefit for the Pfizer-BioNTech COVID-19 vaccine and fulfill the data requirements outlined in the FDA EUA guidance,” the FDA reviewers concluded, suggesting a clear positive view toward the shot.

BNT162b2 has already earned its first global authorization, snagging a go-ahead from the U.K. last week.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...